Siga Technologies Inc (NASDAQ: SIGA)

SIGA Technologies, Inc. is a commercial stage pharmaceutical company. The company concentrates on the development and commercialization of TPOXX, which is the brand name for the antiviral agent tecovirimat. TPOXX has received regulatory approval for the treatment of smallpox and is authorized in several jurisdictions for related orthopoxvirus infections such as monkeypox, cowpox and vaccinia complications following vaccination. SIGA supplies both the oral and intravenous formulations of TPOXX to government stockpiles and to international customers. The firm operates within the biodefense and medical countermeasure segment of the broader pharmaceutical industry. Its activities include formulation, procurement of active pharmaceutical ingredient through third party manufacturers, and fulfillment of supply contracts with national authorities. The company’s strategy centers on maintaining readiness for public health threats while expanding its product footprint through regulatory approvals and strategic partnerships.

SIGA generates revenue chiefly from the sale of oral TPOXX and intravenous TPOXX to the U. S. government and to foreign governments. The primary source of income is the BARDA contract which provides payments for delivery of drug courses to the Strategic National Stockpile and for associated activities such as advanced development, post marketing studies and pediatric formulation work. Additional revenue comes from purchase orders placed by the U. S. Department of Defense for both oral and intravenous product. Internationally, SIGA sells TPOXX directly to foreign health agencies or through distributors who handle local marketing and logistics. The company also recognizes revenue from milestone payments and option exercises under its long term agreements with BARDA. Cash is received monthly as services are performed or goods are delivered under these contracts. Overall, the revenue model is built around predictable government procurement and opportunistic international sales.

SIGA holds a specialized position in the medical countermeasure market as one of the limited suppliers of an FDA approved smallpox antiviral. Its main competitors in the biodefense arena include Emergent BioSolutions Inc. and Bavarian Nordic A/S which offer vaccines and therapeutic agents for similar threats. SIGA’s competitive advantages stem from its early regulatory approvals, a broad patent portfolio covering multiple formulations of tecovirimat, and its established role as a supplier to the U. S. Strategic National Stockpile. The company benefits from long term contracts that provide visibility into future cash flows and from the public health priority placed on smallpox preparedness. These factors create barriers to entry for new entrants and support SIGA’s ability to maintain pricing power in its niche market.

SIGA’s customer base consists principally of U. S. federal agencies such as the Biomedical Advanced Research and Development Authority and the Department of Defense which procure TPOXX for national stockpiles and operational readiness. Foreign governments across Europe, Asia, Africa and the Americas also purchase the drug to strengthen their own preparedness programs. In certain regions, SIGA works with distributors like Meridian Medical Technologies to reach local health authorities and hospitals. The company’s sales are driven by government budget allocations for biodefense and by emerging demand for orthopoxvirus treatments following outbreaks such as the 2022 monkeypox event. Overall, the customer base is concentrated among public sector buyers with occasional private sector involvement through distribution agreements.